ΔN p73 Antibody (4H223): sc-70966
- ΔN p73 Antibody (4H223) is a mouse monoclonal IgG1 ΔN p73 antibody, cited in 3 publications, provided at 100 µg/ml
- raised against amino acids 2-13 of ΔN p73 of human origin
- recommended for detection of ΔN p73 of mouse, rat and human origin by WB; non cross-reactive with full-length p73
- See p73 (E-4): sc-17823 for ΔN p73 antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for ΔN p73 Antibody (4H223). This work is in progress.
QUICK LINKS
ΔN p73 Antibody (4H223) is a mouse monoclonal IgG1 antibody engineered to detect the ΔN p73 protein, also known as Np73 or tumor protein p73, in mouse, rat, and human samples through western blotting (WB) applications. ΔN p73 monoclonal antibody (4H223) targets an epitope within amino acids 2-13 of the ΔN p73 isoform, ensuring selective recognition without cross-reactivity with the full-length p73 protein. The ΔN p73 protein is an N-terminally truncated variant of the TP73 gene product, which plays a pivotal role in regulating cellular processes such as apoptosis, cell cycle progression, and tumor suppression. Unlike its full-length counterpart, TAp73, ΔN p73 lacks the transactivation domain and functions as a dominant-negative inhibitor of both wild-type p53 and TAp73. This inhibitory action is crucial in cancer biology, as ΔN p73 is frequently overexpressed in various malignancies, contributing to tumor growth, drug resistance, and the evasion of apoptosis. By antagonizing the tumor-suppressive functions of p53 and TAp73, ΔN p73 promotes cellular survival and proliferation, making ΔN p73 a significant target for cancer research and therapeutic intervention. Understanding the mechanisms by which ΔN p73 regulates these pathways is essential for developing strategies to counteract pro-tumorigenic effects. Anti-ΔN p73 antibody (4H223) provides researchers with a reliable tool to investigate the expression and functional dynamics of ΔN p73 in cancer models, facilitating advancements in the development of targeted therapies aimed at restoring normal p53 and TAp73 activity. ΔN p73 (4H223) antibody is an indispensable resource for studies focused on the molecular underpinnings of tumor progression and the identification of novel cancer treatment approaches.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
ΔN p73 Antibody (4H223) References:
- Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. | Ishimoto, O., et al. 2002. Cancer Res. 62: 636-41. PMID: 11830511
- Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. | Casciano, I., et al. 2002. Cell Death Differ. 9: 246-51. PMID: 11859407
- Role of methylation in the control of DeltaNp73 expression in neuroblastoma. | Casciano, I., et al. 2002. Cell Death Differ. 9: 343-5. PMID: 11859417
- Human cytomegalovirus induces drug resistance and alteration of programmed cell death by accumulation of deltaN-p73alpha. | Allart, S., et al. 2002. J Biol Chem. 277: 29063-8. PMID: 12034725
- DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. | Zaika, AI., et al. 2002. J Exp Med. 196: 765-80. PMID: 12235210
- Evidence that DeltaNp73 promotes neuronal survival by p53-dependent and p53-independent mechanisms. | Lee, AF., et al. 2004. J Neurosci. 24: 9174-84. PMID: 15483136
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ΔN p73 Antibody (4H223) | sc-70966 | 100 µg/ml | $322.00 |